Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
retaonelabs.com
Reta One Labs holds a Disclosed Labs trust grade of B (89/100), computed independently from 41 lab Certificates of Analysis (as of July 2026). That's a strong, well-documented track record. Scores come only from lab COAs; vendors can't pay to raise them.
What is Reta One Labs's trust score?
Reta One Labs scores 89/100 (Grade B) on Disclosed Labs, from 41 lab COAs (as of July 2026).
How is Reta One Labs's trust score calculated?
Only from lab-issued Certificates of Analysis — average purity, safety-panel coverage, lab corroboration, and forgery signals. No vendor can pay to change it, and sponsorships never affect it.
Samples
Passed
Failed
Trust score updated: July 1, 2026 · 100% pass rate
Composite score based on 41 COAs attributed to this vendor.
Mean HPLC purity across published COAs
Per-peptide coverage of the safety panels each product form requires — identity, net-content, heavy-metals and residual-solvents for raw powders, plus endotoxin and sterility for injectables. Forms aren't penalized for panels they don't need.
Lab corroboration tier — confirmed via public verify portal (90), presumptive trusted lab (85), lab resolved but unverified (75), or no lab attribution (50)
Inverse of CoaFlag count (lot collisions, hash collisions, etc.)
Composite of 41 COAs attributed to this vendor. Last recomputed 2026-07-01.
| Date | Peptide | Test | Result | Purity | Lab | Notes |
|---|---|---|---|---|---|---|
| May 28, 2026 | Bacteriostatic Water | Identity & safety panels | PASS | -- | Kovera Labs | Lot BW78916 · Report KVR-2026-9E5AF7 |
| Feb 23, 2026 | Semaglutide | HPLC purity | PASS | 99.76% | Vanguard Laboratory | Lot SM100326 · Report V260217-6 |
| Feb 23, 2026 | Semaglutide | HPLC purity | PASS | 99.31% | Vanguard Laboratory |
Research profiles — side effects, mechanism, and lab-tested COA data for each peptide in this vendor's catalog.
Add a live, data-driven trust badge to your site or review. It updates automatically when new COAs are indexed — no account required.
Preview
Live badge (JavaScript)
<script async src="https://www.disclosedlabs.com/widget.js" data-vendor="reta-one-labs"></script>
Renders the dynamic grade badge. Best visual; the link is injected by script.
Static link (HTML) — best for SEO
<a href="https://www.disclosedlabs.com/vendors/retaonelabs.com" rel="noopener" target="_blank" style="display:inline-flex;align-items:center;gap:8px;padding:8px 12px;border:1px solid #e2e8f0;border-radius:10px;background:#fff;color:#0f172a;text-decoration:none;font:600 13px/1.25 -apple-system,BlinkMacSystemFont,'Segoe UI',Roboto,Helvetica,Arial,sans-serif"> ✓ Verified by Disclosed Labs — independent COA trust score </a>
A plain, crawlable dofollow link in your page source. This is the version search engines credit.
Both point to Reta One Labs's live profile at https://www.disclosedlabs.com/vendors/retaonelabs.com.
Links back to Reta One Labs's profile — a dofollow link (no sponsored or nofollow tagging). Score updates daily. Dark theme & options →
| BPC-157 | vial | 10mg | $39.00 | $3.90 | In stock | 2026-07-07 | View → |
| GHK-Cu | vial | 50mg | $29.00 | $0.58 | Sold out | 2026-07-07 | View → |
| GHK-Cu | vial | 100mg | $49.00 | $0.49 | In stock | 2026-07-07 | View → |
| MOTS-c | vial | 10mg | $29.00$31.00 | $2.90 | In stock | 2026-07-07 | View → |
| MOTS-c | vial | 40mg | $72.00 | $1.80 | Sold out | 2026-07-07 | View → |
| Retatrutide | vial | 60mg | $239.00 | $3.98 | In stock | 2026-07-07 | View → |
| Tesamorelin | vial | 10mg | $39.00$49.00 | $3.90 | In stock | 2026-07-07 | View → |
| Tesamorelin | vial | 20mg | $92.00 | $4.60 | In stock | 2026-07-07 | View → |
Prices are scraped from retaonelabs.comand may lag the live site. All prices are single-vial / pre-bulk list prices — bulk or bundle deals may be lower. $/mg is derived from the listed strength. “Updated” is when we last verified each listing.
We are continuously testing more products. Scores update with each new result.
Read our scoring methodology →Trust scores are computed from indexed Certificates of Analysis — vendor-published, and lab-confirmed where a lab copy verifies them — using a fixed, versioned methodology (v16). They are not based on independent blind-purchase testing, and no vendor can pay for placement or a higher score. How we score · How we make money
PMB address (-0.03), No business entity (-0.03), Lab-confirmed (0.02)
Sources: RDAP/WHOIS for domain data, Twilio Lookup for phone classification, Google Places for address verification. Crawl runs weekly. Signals are independent of vendor-supplied data.
| Lot SM200326 · Report V260217-6 |
| Dec 16, 2025 | Retatrutide | HPLC purity | PASS | 99.48% | Vanguard Laboratory | Lot R61025 · Report V251216-6 004 |
| Oct 22, 2025 | Tesamorelin | HPLC purity | PASS | 99.34% | Vanguard Laboratory | Lot TS101125 · Report V251021-17 002 |
| Oct 3, 2025 | Tirzepatide | HPLC purity | PASS | 99.8% | Vanguard Laboratory | Lot TR300925 · Report V251002-16 001 |
| Oct 3, 2025 | Tirzepatide | HPLC purity | PASS | 99.88% | Vanguard Laboratory | Lot TR301025 · Report V251002-16 |
| Sep 24, 2025 | Tirzepatide | HPLC purity | PASS | 99.872% | Chromate | Lot TR600925 · Report 28076 |
| Sep 24, 2025 | BPC-157 | HPLC purity | PASS | 99.364% | Chromate | Lot Bp100925 · Report 28073 |
| Sep 24, 2025 | GHK-Cu | HPLC purity | PASS | 99.708% | Chromate | Lot GK500925 · Report 28074 |
| Sep 9, 2025 | Retatrutide | HPLC purity | PASS | 99.755% | Chromate | Lot R30725 · Report 27605 |
| Sep 9, 2025 | Retatrutide | HPLC purity | PASS | 99.498% | Chromate | Lot R20725 · Report 27606 |
| Sep 8, 2025 | Retatrutide | HPLC purity | PASS | 99.302% | Chromate | Lot R10725 · Report 28075 |
| Aug 18, 2025 | Retatrutide | HPLC purity | PASS | 99.839% | Chromate | Lot R50725 · Report 27021 |
| Jul 8, 2026 | Retatrutide | HPLC purity | PASS | 99.857% | Kovera Labs | Lot RT300326 · Report KVR-2026-C3824D |
| Jul 8, 2026 | Retatrutide | HPLC purity | PASS | 99.888% | Kovera Labs | Lot RT500326 · Report KVR-2026-D36F55 |
| Jul 8, 2026 | Retatrutide | HPLC purity | PASS | 99.8% | Vanguard Laboratory | Lot R401125 · Report V251029-12 003 |
| Jul 8, 2026 | PT-141 | HPLC purity | PASS | 99.865% | Kovera Labs | Lot PT100526 · Report KVR-2026-4A3B51 |
| Jul 8, 2026 | CJC-1295 (No DAC)/Ipamorelin | HPLC purity | PASS | 99.774% | Kovera Labs | Lot CJIP0326 · Report KVR-2026-7FC973 |
| Jul 8, 2026 | NAD+ | HPLC purity | PASS | 99.885% | Kovera Labs | Lot NAD5000526 · Report KVR-2026-EE59DB |
| Jul 8, 2026 | MOTS-c | HPLC purity | PASS | 99.948% | Kovera Labs | Lot MTS400526 · Report KVR-2026-C92C0E |
| Jul 8, 2026 | Tesamorelin | HPLC purity | PASS | 99.922% | Kovera Labs | Lot TS100326 · Report KVR-2026-4A9814 |
| Jul 8, 2026 | GHK-Cu | HPLC purity | PASS | 99.862% | Kovera Labs | Lot GK1000426 · Report KVR-2026-7CF218 |
| Jul 8, 2026 | Klow | HPLC purity | PASS | 99.908% | Kovera Labs | Lot KL800526 · Report KVR-2026-84E44E |
| Jul 8, 2026 | Tirzepatide | HPLC purity | PASS | 99.901% | Kovera Labs | Lot TZ600326 · Report KVR-2026-5CF3DD |
| Jul 8, 2026 | Glow | HPLC purity | PASS | 99.763% | Kovera Labs | Report KVR-2026-51E157 |
| Jul 8, 2026 | Retatrutide | Identity & safety panels | PASS | -- | Vanguard Laboratory | Lot R601025 · Report V251029-12 004 |
| Jul 8, 2026 | KLOW | HPLC purity | PASS | 99% | Vanguard Laboratory | Lot KL801025 · Report V251029-12 001 |
| Jul 8, 2026 | MOTS-c | HPLC purity | PASS | 99.238% | Kovera Labs | Lot MTS100626 · Report KVR-2026-7DA118 |
| Jul 8, 2026 | BPC-157/TB-500 | HPLC purity | PASS | 99.649% | Kovera Labs | Report KVR-2026-8F88BE |
| Jul 8, 2026 | Tesamorelin | HPLC purity | PASS | 99.888% | Kovera Labs | Lot TS200526 · Report KVR-2026-B61789 |
| Jul 8, 2026 | NAD+ | HPLC purity | PASS | 99% | Vanguard Laboratory | Lot NAD112025 · Report V251029-12 002 |
| Jul 8, 2026 | Retatrutide | HPLC purity | PASS | 99.832% | Kovera Labs | Lot RT200326 · Report KVR-2026-D6DE97 |
| Jul 8, 2026 | Retatrutide | HPLC purity | PASS | 99.876% | Kovera Labs | Lot RT600326 · Report KVR-2026-E1FE69 |
| Jul 8, 2026 | Retatrutide | HPLC purity | PASS | 99.809% | Kovera Labs | Lot RT100326 · Report KVR-2026-CD3D3A |
| Jul 8, 2026 | SS-31 | HPLC purity | PASS | 99.187% | Kovera Labs | Lot SS100626 · Report KVR-2026-5AEF0F |
| Jul 8, 2026 | Tesamorelin | HPLC purity | PASS | 99.177% | Kovera Labs | Lot TS100526 · Report KVR-2026-2CBF9B |
| Jul 8, 2026 | MOTS-c | HPLC purity | PASS | 99.863% | Kovera Labs | Lot MTS100326 · Report KVR-2026-A3E4B4 |
| Jul 8, 2026 | Tirzepatide | HPLC purity | PASS | 99.881% | Kovera Labs | Lot TZ100326 · Report KVR-2026-A36A5F |
| Jul 8, 2026 | Tirzepatide | HPLC purity | PASS | 99.92% | Kovera Labs | Lot TZ300326 · Report KVR-2026-DA084C |
| Jul 8, 2026 | Tirzepatide | HPLC purity | PASS | 99.956% | Kovera Labs | Lot TR300626 · Report KVR-2026-F5D17E |